Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)
Open Access
- 17 May 2003
- journal article
- research article
- Published by Wiley in FEBS Letters
- Vol. 545 (2-3) , 144-150
- https://doi.org/10.1016/s0014-5793(03)00523-4
Abstract
For reversal of MDR1 gene‐dependent multidrug resistance (MDR), two small interfering RNA (siRNA) constructs were designed to inhibit MDR1 expression by RNA interference. SiRNA duplexes were used to treat human pancreatic carcinoma (EPP85‐181RDB) and gastric carcinoma (EPG85‐257RDB) cells. In both cellular systems, siRNAs could specifically inhibit MDR1 expression up to 91% at the mRNA and protein levels. Resistance against daunorubicin was decreased to 89% (EPP85‐181RDB) or 58% (EPG85‐257RDB). The data indicate that this approach may be applicable to cancer patients as a specific means to reverse tumors with a P‐glycoprotein‐dependent MDR phenotype back to a drug‐sensitive one.Keywords
This publication has 24 references indexed in Scilit:
- Specific inhibition of bcr-abl gene expression by small interfering RNABlood, 2003
- RNA interferenceNature, 2002
- Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cellsZeitschrift für Krebsforschung und Klinische Onkologie, 2002
- A System for Stable Expression of Short Interfering RNAs in Mammalian CellsScience, 2002
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- ATP Requirements and Small Interfering RNA Structure in the RNA Interference PathwayCell, 2001
- Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance–associated ABC transporter BCRP/MXR/ABCG2Cancer Gene Therapy, 2001
- Kinetic characterization of ribozymes directed against the cisplatin resistance–associated ABC transporter cMOAT/MRP2/ABCC2Cancer Gene Therapy, 2001
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI Journal of the National Cancer Institute, 1990